92 results about "Bordetella pertussis" patented technology

A method for targeting, treating, or diagnosing malignant mammalian tumor cells, comprising administering an effective amount of a β1,6-branched oligosaccharide specific binding agent to the mammal. As a treatment, the binding agent may be intrinsically cytotoxic, initiate an endogenous cytotoxic cascade, or play a role in a cytotoxic cascade involving exogenous factors. A preferred binding agent is Bordetella pertussis, which is both specific for the β1,6-branched oligosaccharide and well tolerated. Genetically engineered organisms may also be employed. Pharmaceutical compositions may also serve as binding agents.

Diagnostic testing and immunomonitoring that uses genetically detoxified Bordetella pertussis CyaA as a delivery system are effective in tracking any immune responses, such as those generated by infectious and non-infectious diseases, or vaccinations, for example. T cells previously stimulated by a given antigen can be restimulated in vitro by the same antigen fused or chemically coupled to CyaA or a fragment thereof. The invention includes diagnostic tests and immunomonitoring for tuberculosis by providing a delivery system, which can deliver the M. tuberculosis immunodominant proteins ESAT-6 and CFP-10, to human cells and non-human animal cells, such as cattle. In addition, fusion proteins between CyaA and cancer antigens are also provided as diagnostic tests and immunomonitoring systems for cancers, such as melanoma.

A method for cloning PRN FIM2 and FIM3 genes from Bordetella pertussis CS strain and prokaryotic expressed recombinant protein by expression carrier are disclosed. The procedure is carried out by cloning CS strain to obtain PRN, FIM2 and FIM3 genes, sub-cloning to expression carriers separately, constructing FIM2-FIM3 fused gene expression plasmid, inducing and expressing in colibacillus. It has excellent immune protection and immunogenicity. They can be used as pertussis vaccine antigen active ingredients.

The invention discloses a primer group for detecting Bordetella pertussis, a detection test kit and a detection method. The primer group comprises an IS481 gene amplification pair and/or a PT gene amplification primer pair, wherein the primer pair sequence of the IS481 gene amplification pair is a nucleotide sequence shown as SEQ IDNO:1 and SEQ IDNO:2, and the primer pair sequence of the PT gene amplification primer pair is a nucleotide sequence shown as SEQ IDNO:3 and SEQ IDNO:4. The invention detects two genes simultaneously in the same reaction system, and the two genes can be detected through gel electrophoresis. The specificity of detection is guaranteed, and the sensitivity of detection is increased; meanwhile, detection efficiency is greatly increased, and detection cost is saved.

The invention discloses a kit for rapidly detecting bordetella pertussis and a detection method thereof. A specific probe is combined with a high-tolerance polymerase technology, a sample can be directly amplified after simple heating treatment, a nucleic acid extraction step is not needed, and the sample treatment time of a pertussis sample is shortened. The components used for detecting bordetella pertussis are prepared into a dry powder preparation, so that the thermal stability of the kit is remarkably improved, and the kit can be used for normal-temperature transportation. The single-tubepackaging of the multi-component dry powder reduces the step of liquid preparation. Experimental results prove that the kit and the detection method thereof are strong in specificity, high in sensitivity and simple to operate, and can be used for directly, quickly and accurately detecting the bordetella pertussis.

The invention belongs to the field of protein separating purification and relates to an industrialized large-scale separating purification method of 69KD outer membrane protein of pertussis bacillus. The method comprises extracting pertussis bacillus CS thallus in buffer solution with potential of hydrogen (pH) 8.8 and containing sodium chloride of 1mol/L to 2mol/l for thirty minutes to three hours at 40 to 60 DEG C, performing centrifugation, collecting supernatant, and obtaining thallus lysate supernatant of the 69KD outer membrane protein; b adding ammonium sulfate into the thallus lysate supernatant of the 69KD outer membrane protein to enable the ammonium sulfate to achieve 15% weight/volume to 25% weight/volume, standing the solution for one hour to eight hours, performing centrifugation, and collecting the supernatant; c adding ammonium sulfate into the supernatant collected in step b to enable the ammonium sulfate to achieve 30% weight/volume to 38% weight/volume, standing the solution for one hour to eight hours, performing centrifugation, abandoning the supernatant, and collecting deposit; d dissolving the deposit collected in the step c through Tris-HCl buffer solution, and dialyzing the solution to remove the ammonium sulfate; and e enabling the solution to pass through a diethyl aminoethyl (DEAE) sepharose ion exchange column, utilizing buffer solution with linear gradient sodium chloride concentration from 0 mol/L to 1 mol/L for washing, and collecting objective protein. The purification method for the 69KD outer membrane protein of the pertussis bacillus can fast and conveniently purify natural conformation 69 KD outer membrane protein so that the method can be applied to large-scale industrial preparation of the natural configuration 69 KD outer membrane protein.

The invention relates to a suspension microbead array system for detecting common pathogens of the respiratory tract infection. The system detects influenza A virus, influenza B virus, parainfluenza virus, human metapneumovirus, rhinovirus, bocavirus, adenovirus, respiratory syncytial virus, mycoplasma pneumoniae, moraxella catarrhalis, haemophilus influenza, streptococcus pneumoniae and bordetella pertussis in one experiment. The suspension microbead array system finishes the detection of 8 viruses, 4 bacteria and 1 mycoplasma in one experiment, prevents leak detection to the greatest extent, and is beneficial for the targeted clinical treatment; the cost of reagents, if divided on the detection of each index, is greatly lowered, so that the medical cost is reduced.

The invention relates to an oligonucleotide sequence combination for specific detection of bordetella pertussis and bordetella parapertussis nucleic acids existing in a sample with the adoption of fluorescent PCR (polymerase chain reaction), and a kit containing the combination. The kit can sensitively detect the bordetella pertussis nucleic acid and the bordetella parapertussis nucleic acid existing in the sample with a detection lower limit of 20 copies in each reaction system, and has important application value in the fields such as disease surveillance and clinical diagnosis.

The invention discloses a primer group, a kit and a method for detecting respiratory pathogens and relates to the technical field of respiratory pathogen detection. The primer group for detecting therespiratory pathogens comprises, such as, one or a combination of several of a first primer to a thirteenth primer. The primer group can realize detection of common respiratory pathogens such as a respiratory syncytial virus, an adenovirus, a human metapneumovirus, a rhinovirus/enterovirus, a parainfluenza virus, a coronavirus, a bocavirus, an influenza virus A, an influenza virus B, bordetella pertussis, bordetella parapertussis, mycoplasma pneumoniae and chlamydia pneumoniae and has the characteristics of relatively high sensitivity and specificity, low cost, convenience in detection, relatively good repeatability and the like.

The invention relates to the technical field of biologic pharmacy, and discloses a method for removing pertussis component pilin 2/3 endotoxin. The method comprises the steps that after bordetella pertussis is fermented and cultured, thalli are centrifugally collected, thalli are extracted through a urea phosphate buffer solution, a supernate is centrifugally collected, and PEG-8000 and ammonium sulfate are used for performing precipitation; precipitates are extracted by the phosphate buffer solution, then, a supernate is centrifugally collected, a Q-Sepharose chromatographic column is adoptedfor processing, and a phosphate buffer solution containing sodium chloride is adopted for eluting the Fim 2/3 component. By combining PEG8000 precipitating, ammonia sulfate precipitating and Q-Sepharose chromatographic column processing are combined, endotoxin in pilin 2/3 is removed through repeated means, on the premise of not introducing allogenic materials, the effective ingredient Fim 2/3 biologic activity and recycling rate are kept, and meanwhile the endotoxin in Fim 2/3 can be removed to 10 EU/mg or lower.

The invention relates to a pertussis genetic-engineering fused subunit vaccine, which is fused protein produced by connecting pertussis toxin S1 subunit mutant with a peptide Fs. The invention also relates to a preparation method of bordetella pertussis double-subunit genetic engineering vaccine. The invention, which overcomes a variety of deficiencies of the traditional vaccine and the traditional preparation method, has the advantages of mass production potential, easy operation, high security, small side effect and no reverse mutation.

The invention relates to a bordetella pertussis PT (pertussis toxin) antigen monoclonal antibody and application thereof, and belongs to the field of preparation of biological products. The bordetella pertussis PT antigen monoclonal antibody is secreted by hybridoma cell strains capable of stably secreting bordetella pertussis FT antigen monoclonal antibodies, and a preservation number of the hybridoma cell strains is CGMCC No.10588. The bordetella pertussis PT antigen monoclonal antibody and the application have the advantages that the monoclonal antibody is high in potency and good in specificity, and can be applied to monitoring the quality in bordetella pertussis vaccine production procedures, carrying out enzyme-linked immunosorbent assay on contents of PT components in finished vaccine and preparing bordetella pertussis PT antigen enzyme-linked immune monitoring reagents or enzyme-linked immune monitoring reagent kits.

The present invention relates to methods of identifying compounds that inhibit the activation between a biomolecule, pharmaceutical compositions comprising such compounds, and methods of treating and/or to reducing the risk of Bacillus anthracis and Bordetella pertussis infection by administering such pharmaceutical compositions.

The invention discloses a production method of an acellular pertussis vaccine. The production method comprises the following steps of: fermenting and purifying a Fha bordetella pertussis genetic engineering strain in which pt gene is knocked out to obtain an antigen component fha; fermenting and purifying the Pt bordetella pertussis genetic engineering strain in which fha gene is knocked out to obtain an antigen component pt; fermenting and purifying Prn bordetella pertussis genetic engineering strain in which fha gene is knocked out to obtain an antigen component prn; and preparing the acellular pertussis vaccine from the antigen components fha, pt and prn. According to the method, high-efficiency expression of a single target antigen can be realized, so that the growing speed of the bordetella pertussis genetic engineering strain is remarkably accelerated, and the production time and production cost can be reduced.

The invention discloses a kit and a method for fluorescent quantitative detection of Bordetella pertussis, and provides a fluorescent quantitative reagent for detecting the Bordetella pertussis. The fluorescent quantitative reagent comprises a primer 1 for detecting the Bordetella pertussis, a primer 2 for detecting the Bordetella pertussis and a probe 1 for detecting the Bordetella pertussis. Experimental results prove that the kit and the detection method is based on Taqman fluorescent quantitative detection technique, pathogens of infection can be rapidly defined, detection expense is decreased, use efficiency of instruments is improved, and the method solves the problem of flux of clinical respiratory fungus infection pathogen detection and has important guide significance for clinical early diagnosis and treatment.

The present invention provides a vaccine production strain of Bordetella bronchiseptica that produces a pertussis toxin in high yield. The present invention provides a method for creating a Bordetella bronchiseptica cell line which produces a Bordetella pertussis toxin comprising the steps of introducing a plasmid containing a DNA encoding antibiotic resistance into a Bordetella bronchiseptica strain, selecting for isolates in which the DNA encoding antibiotic resistance is recombinantly incorporated into the chromosome in place of the Bordetella bronchiseptica toxin gene, introducing a plasmid containing DNA encoding subunits of the Bordetella pertussis toxins into the Bordetella bronchiseptica isolates; and, selecting for isolates in which DNA encoding Bordetella pertussis toxin subunit is recombinantly incorporated into the chromosome, the resulting cells producing the Bordetella pertussis toxin. The present invention further provides a method for creating a Bordetella bronchiseptica cell line which produces a Bordetella pertussis toxin and does not express filamentous hemagglutinin.

The invention discloses a primer probe combination. The primer probe combination includes primers and a probe for detecting Bordetella pertussis, the primers for detecting the Bordetella pertussis includes an upstream primer and a downstream primer, wherein the upstream primer for detecting Bordetella pertussis is shown as SEQ ID NO. 1 in a sequence table; the downstream primer for detecting Bordetella pertussis is shown as SEQ ID NO. 2 in the sequence table; the probe used for detecting Bordetella pertussis is shown as SEQ ID NO. 3 in the sequence table. Based on the primer probe combination, the invention further provides a PCR reaction liquid, a kit and an application thereof. According to the primer probe combination and the kit, the primer pair and the probe with good specificity are designed based on the gene sequence of Bordetella pertussis, the kit can only detect Bordetella pertussis, and the specificity of the kit is good.